Compass Therapeutics, Inc. CMPX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Compass Therapeutics, Inc. (CMPX) is a healthcare company listed in the US with a market value of about $139M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -35%.
About Compass Therapeutics
Compass Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 7 years in our data. Its share count rose by 50% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850000 | $0 | — | — | — | — |
| Net income | -$66M | -$49M | -$42M | -$39M | -$82M | -$30M | -$35M |
| Free cash flow | -$49M | -$45M | -$41M | -$34M | -$21M | -$27M | -$32M |
| EPS (diluted) | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 | $-0.96 | $-5.19 |
| Net margin | — | -5808.8% | — | — | — | — | — |
| ROIC | -27.9% | -33.9% | -33.5% | -22.6% | -56.8% | -44.6% | -102.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Compass Therapeutics pay a dividend?
Not currently.
Is Compass Therapeutics a good stock to buy?
We do not give buy or sell advice. Compass Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.